A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as
a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.